PH12015502075B1 - Treatment of cataplexy - Google Patents

Treatment of cataplexy

Info

Publication number
PH12015502075B1
PH12015502075B1 PH12015502075A PH12015502075A PH12015502075B1 PH 12015502075 B1 PH12015502075 B1 PH 12015502075B1 PH 12015502075 A PH12015502075 A PH 12015502075A PH 12015502075 A PH12015502075 A PH 12015502075A PH 12015502075 B1 PH12015502075 B1 PH 12015502075B1
Authority
PH
Philippines
Prior art keywords
cataplexy
treatment
subject
administering
need
Prior art date
Application number
PH12015502075A
Other languages
English (en)
Other versions
PH12015502075A1 (en
Inventor
Moise A Khayrallah
Gary Bream
Stephen E Butts
Original Assignee
Aerial Biopharma Llc
Sk Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51530017&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12015502075(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aerial Biopharma Llc, Sk Biopharmaceuticals Co Ltd filed Critical Aerial Biopharma Llc
Publication of PH12015502075A1 publication Critical patent/PH12015502075A1/en
Publication of PH12015502075B1 publication Critical patent/PH12015502075B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/02Carbamic acids; Salts of carbamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/02Halogenated hydrocarbons
    • A61K31/025Halogenated hydrocarbons carbocyclic
    • A61K31/03Halogenated hydrocarbons carbocyclic aromatic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/325Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PH12015502075A 2013-03-13 2015-09-11 Treatment of cataplexy PH12015502075B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361778998P 2013-03-13 2013-03-13
PCT/US2014/023969 WO2014164969A1 (en) 2013-03-13 2014-03-12 Treatment of cataplexy

Publications (2)

Publication Number Publication Date
PH12015502075A1 PH12015502075A1 (en) 2016-01-18
PH12015502075B1 true PH12015502075B1 (en) 2016-01-18

Family

ID=51530017

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12015502075A PH12015502075B1 (en) 2013-03-13 2015-09-11 Treatment of cataplexy

Country Status (21)

Country Link
US (7) US9359290B2 (enExample)
EP (1) EP2968208B1 (enExample)
JP (2) JP6530741B2 (enExample)
KR (1) KR102192554B1 (enExample)
CN (1) CN105431142B (enExample)
AU (1) AU2014248849B2 (enExample)
BR (1) BR112015022197B1 (enExample)
CA (1) CA2905457A1 (enExample)
DK (1) DK2968208T3 (enExample)
ES (1) ES2927675T3 (enExample)
HR (1) HRP20221018T1 (enExample)
HU (1) HUE060060T2 (enExample)
MX (1) MX381381B (enExample)
MY (1) MY177740A (enExample)
PH (1) PH12015502075B1 (enExample)
PT (1) PT2968208T (enExample)
RU (2) RU2689984C2 (enExample)
SG (1) SG11201507121RA (enExample)
SI (1) SI2968208T1 (enExample)
TW (2) TWI663971B (enExample)
WO (1) WO2014164969A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0613697A2 (pt) * 2005-06-08 2011-01-25 Sk Holdings Co Ltd tratamento de distúrbios de sono-vigìlia
RU2567801C2 (ru) * 2009-06-22 2015-11-10 Ск Биофармасъютиклс Ко., Лтд. Способы лечения и профилактики усталости
PT2968208T (pt) * 2013-03-13 2022-10-28 Aerial Biopharma Llc Tratamento da cataplexia
PT3021838T (pt) 2013-07-18 2020-09-01 Sk Biopharmaceuticals Co Ltd Tratamento para a obesidade
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
CA3036071A1 (en) 2016-09-06 2018-03-15 Jazz Pharmaceuticals International Iii Limited Solvate form of (r)-2-amino-3-phenylpropyl carbamate
US10195151B2 (en) 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
EP3523275B1 (en) 2016-10-06 2023-09-27 Axsome Malta Ltd. Carbamoyl phenylalaninol compounds for medical use
EP3630072A4 (en) 2017-06-02 2021-03-10 Jazz Pharmaceuticals Ireland Limited METHODS AND COMPOSITIONS FOR TREATMENT OF EXCESSIVE Drowsiness
KR102643275B1 (ko) 2017-07-31 2024-03-04 재즈 파마슈티칼즈 아일랜드 리미티드 카바모일 페닐알라니놀 유사체 및 이의 용도
EP3661507A4 (en) * 2017-09-12 2020-11-18 Ovid Therapeutics Inc. USE OF GABOXADOL TO TREAT NARCOLEPSIA
US12419832B2 (en) 2018-01-29 2025-09-23 Cognos Therapeutics, Inc. Intratumoral delivery of bortezomib
US20190381056A1 (en) 2018-06-17 2019-12-19 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
US20200147093A1 (en) * 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
US11020402B2 (en) 2018-10-15 2021-06-01 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
WO2021113163A1 (en) * 2019-12-03 2021-06-10 Axsome Therapeutics, Inc. Use of reboxetine to treat nervous system disorders
KR20240119194A (ko) * 2018-10-15 2024-08-06 액섬 테라퓨틱스, 인크. 기면증 치료를 위한 레복세틴의 용도
BR112021013766A2 (pt) 2019-03-01 2021-09-21 Flamel Ireland Limited Composições de gama-hidroxibutirato com farmacocinética melhorada no estado alimentado
MX2022006630A (es) * 2019-12-03 2022-06-24 Axsome Therapeutics Inc Uso de reboxetina para tratar los trastornos del sistema nervioso.
TW202139986A (zh) 2020-02-21 2021-11-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 治療原發性嗜睡症之方法
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function
KR102390194B1 (ko) * 2020-08-03 2022-04-25 셀라이온바이오메드 주식회사 페닐알킬 카바메이트 화합물을 포함하는 Kca3.1채널 매개질환 치료용 조성물
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
WO2025006965A1 (en) 2023-06-29 2025-01-02 Axsome Therapeutics, Inc. Methods of administering solriamfetol to lactating women
WO2025042959A1 (en) * 2023-08-21 2025-02-27 Axsome Therapeutics, Inc. Use of solriamfetol for the treatment of orphan diseases

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US178429A (en) * 1876-06-06 Improvement in hulling-machines
CZ285762B6 (cs) 1993-06-10 1999-11-17 Eli Lilly And Company Farmaceutický prostředek vhodný pro prevenci dávení a zvracení a pro ošetřování sexuální dysfunkce savců a jeho použití
KR100197892B1 (ko) 1994-09-09 1999-06-15 남창우 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법
KR0173862B1 (ko) 1995-02-11 1999-04-01 조규향 O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
US5756817C1 (en) 1995-02-11 2001-04-17 Sk Corp O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same
KR0173863B1 (ko) 1995-04-10 1999-04-01 조규향 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
ES2170878T3 (es) 1996-10-10 2002-08-16 Sk Corp Compuestos de o-carbamoil-fenilalaninol y sus sales farmaceuticamente utiles.
AU4674797A (en) 1996-10-22 1998-05-15 Ortho Pharmaceutical Corporation Phenylalaninol derivatives for the treatment of central nervous system disorders
US6204245B1 (en) * 1999-09-17 2001-03-20 The Regents Of The University Of California Treatment of narcolepsy with immunosuppressants
GB0109103D0 (en) * 2001-04-11 2001-05-30 Pfizer Ltd Novel compounds
US20030207857A1 (en) 2001-04-11 2003-11-06 Adam Mavis D. Phenyl heterocyclyl ethers
US20050080268A1 (en) 2003-10-08 2005-04-14 Yong-Moon Choi Process of preparing O-carbamoyl compounds in the presence of active amine group
AU2005231375A1 (en) * 2004-03-31 2005-10-20 Janssen Pharmaceutica, N.V. Non-imidazole heterocyclic compounds as histamine H3 receptor modulators
MX2007002682A (es) * 2004-09-07 2008-03-05 Orphan Medical Inc Composiciones mejoradas de gamma-hidroxibutirato ghb.
MX2007005172A (es) 2004-10-28 2007-06-22 Sk Corp Terapia adjunta para la depresion.
BRPI0613697A2 (pt) 2005-06-08 2011-01-25 Sk Holdings Co Ltd tratamento de distúrbios de sono-vigìlia
KR101335942B1 (ko) 2005-06-22 2013-12-04 에스케이바이오팜 주식회사 성기능 장애의 치료
BRPI0520451A2 (pt) 2005-07-26 2009-05-12 Janssen Pharmaceutica Nv métodos para tratamento de distúrbios associados a substáncias quìmicas
FR2903904A1 (fr) * 2006-07-21 2008-01-25 Bioprojet Soc Civ Ile Association de modafinil et d'un antagoniste ou agoniste inverse du recepteur h3
MX2009003926A (es) 2006-10-13 2009-06-26 Janssen Pharmaceutica Nv Composiciones de fenilalquilamino-carbamato.
EP2080012B1 (en) * 2006-11-10 2013-03-20 Dimerix Bioscience Pty.Ltd. Methods for assaying test compounds on associated receptors
RU2567801C2 (ru) * 2009-06-22 2015-11-10 Ск Биофармасъютиклс Ко., Лтд. Способы лечения и профилактики усталости
US8232315B2 (en) 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
US8895609B2 (en) 2009-11-06 2014-11-25 Sk Biopharmaceuticals Co., Ltd. Methods for treating attention-deficit/hyperactivity disorder
CN102781436B (zh) 2009-11-06 2014-01-08 爱思开生物制药株式会社 纤维肌痛综合征的治疗方法
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
PT2968208T (pt) * 2013-03-13 2022-10-28 Aerial Biopharma Llc Tratamento da cataplexia

Also Published As

Publication number Publication date
RU2019114940A (ru) 2019-06-28
HUE060060T2 (hu) 2023-01-28
JP6530741B2 (ja) 2019-06-12
TW201513856A (zh) 2015-04-16
US11072579B2 (en) 2021-07-27
MX2015012644A (es) 2016-06-21
DK2968208T3 (da) 2022-08-22
RU2019114940A3 (enExample) 2019-12-25
BR112015022197A2 (pt) 2017-07-18
US10259780B2 (en) 2019-04-16
EP2968208A1 (en) 2016-01-20
CA2905457A1 (en) 2014-10-09
US20220017457A1 (en) 2022-01-20
MX381381B (es) 2025-03-12
BR112015022197B1 (pt) 2022-06-07
RU2015143610A (ru) 2017-04-20
EP2968208B1 (en) 2022-07-20
US20140275244A1 (en) 2014-09-18
WO2014164969A1 (en) 2014-10-09
US11713292B2 (en) 2023-08-01
JP2016512531A (ja) 2016-04-28
KR102192554B1 (ko) 2020-12-18
US9585863B2 (en) 2017-03-07
RU2689984C2 (ru) 2019-05-30
BR112015022197A8 (pt) 2019-11-26
JP2019147830A (ja) 2019-09-05
CN105431142A (zh) 2016-03-23
US20160250176A1 (en) 2016-09-01
AU2014248849A1 (en) 2015-10-08
US9359290B2 (en) 2016-06-07
US20250059135A1 (en) 2025-02-20
PH12015502075A1 (en) 2016-01-18
EP2968208A4 (en) 2016-10-12
SG11201507121RA (en) 2015-10-29
US20170137375A1 (en) 2017-05-18
ES2927675T3 (es) 2022-11-10
RU2015143610A3 (enExample) 2018-03-21
MY177740A (en) 2020-09-23
TW201919606A (zh) 2019-06-01
HK1219236A1 (zh) 2017-03-31
AU2014248849B2 (en) 2018-08-30
HRP20221018T1 (hr) 2023-01-06
TWI663971B (zh) 2019-07-01
KR20150139522A (ko) 2015-12-11
SI2968208T1 (sl) 2023-02-28
US20230416195A1 (en) 2023-12-28
US20190218174A1 (en) 2019-07-18
US12162821B2 (en) 2024-12-10
TWI684450B (zh) 2020-02-11
PT2968208T (pt) 2022-10-28
CN105431142B (zh) 2019-04-26

Similar Documents

Publication Publication Date Title
PH12015502075A1 (en) Treatment of cataplexy
ZA201708692B (en) Antibacterial compounds
EA201690206A1 (ru) Терапевтически активные соединения и способы их применения
PH12016500164B1 (en) Therapeutically active compounds and their methods of use
BR112018003526A2 (pt) métodos de tratamento de doenças inflamatórias
MY194341A (en) Method of treating a brain tumor
HK1256042A1 (zh) 用於治疗糖尿病周围神经病变的hdac抑制剂
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
PH12015500169A1 (en) Prediction of treatment response to jak/stat inhibitor
EA201591507A1 (ru) Лечение рассеянного склероза лахинимодом
NZ722600A (en) Methods of treating mild brain injury
PH12016500903A1 (en) Novel methods for treating neurodegenerative diseases
PH12014502065A1 (en) Vesicular formulations
MX382608B (es) Tratamiento del prurito urémico.
EA201690446A1 (ru) Лечение множественной миеломы
EA201690445A1 (ru) Лечение рака
MX2017007245A (es) Metodos de tratamiento de la fibrosis.
MX374354B (es) Método de curación de heridas.
EA201691036A1 (ru) Новое соединение для лечения тяжелой гипогликемии
EA201690914A1 (ru) Новое соединение для лечения тяжелой гипогликемии
NZ724799A (en) Compositions and methods for the treatment or prevention of neurodegenerative disorders
UA114811C2 (uk) Застосування акампросату та баклофену для лікування аміотрофічного бічного склерозу
NZ750581A (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
PH12014000104A1 (en) Therapeutic methods and compositions for treating diabetes